➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
McKesson
Johnson and Johnson
Medtronic

Last Updated: June 19, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Fulranumab


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Fulranumab?

Fulranumab is an investigational drug.

There have been 4 clinical trials for Fulranumab. The most recent clinical trial was a Phase 3 trial, which was initiated on July 1st 2015.

The most common disease conditions in clinical trials are Osteoarthritis and [disabled in preview]. The leading clinical trial sponsors are Janssen Research & Development, LLC and [disabled in preview].

There are six US patents protecting this investigational drug and three hundred and fourteen international patents.

Recent Clinical Trials for Fulranumab
TitleSponsorPhase
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002Janssen Research & Development, LLCPhase 3

See all Fulranumab clinical trials

Clinical Trial Summary for Fulranumab

Top disease conditions for Fulranumab
Top clinical trial sponsors for Fulranumab

See all Fulranumab clinical trials

US Patents for Fulranumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fulranumab   Get Started Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Get Started Free
Fulranumab   Get Started Free Binding-triggered transcriptional switches and methods of use thereof The Regents of the University of California (Oakland, CA)   Get Started Free
Fulranumab   Get Started Free Cell culture medium LA JOLLA BIOLOGICS, INC. (San Diego, CA)   Get Started Free
Fulranumab   Get Started Free Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Get Started Free
Fulranumab   Get Started Free Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fulranumab

Drugname Country Document Number Estimated Expiration Related US Patent
Fulranumab Australia AU2013220749 2032-02-15   Get Started Free
Fulranumab Brazil BR112014019627 2032-02-15   Get Started Free
Fulranumab Canada CA2862476 2032-02-15   Get Started Free
Fulranumab China CN104114705 2032-02-15   Get Started Free
Fulranumab China CN108570468 2032-02-15   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Medtronic
McKesson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.